Clinical Study

Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes

Figure 1

(a) Urinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) before and 12-week after treatment with alogliptin. Alogliptin treatment tended to decrease UAlbCR ( versus  mg/g Cr, ). (b) UAlbCR of each participant before and 12-week after treatment with alogliptin.
(a)
(b)